8-KMaterial AgreementsFinancial EventsExhibits & Filings

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (Jan 17, 2012)

Filed January 17, 2012For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on January 16, 2012, detailing significant financing activities related to its pending acquisition of Pharmasset, Inc. The company entered into three new credit agreements totaling $3.00 billion: a $1.25 billion 5-year revolving credit facility, a $750 million short-term revolving credit facility, and a $1 billion term loan facility. These facilities are primarily intended to fund the Pharmasset acquisition, refinance existing debt, and cover related fees and general corporate purposes. Notably, Gilead borrowed $750 million under the 5-year facility and $400 million under the short-term facility on the closing date, with the full $1 billion term loan also drawn at that time, indicating immediate funding needs for the acquisition. In conjunction with these new credit facilities, Gilead Sciences also terminated its previous $1.25 billion Five-Year Revolving Credit Agreement dated December 18, 2007, fully prepaying outstanding obligations. This move signifies a restructuring of Gilead's debt and credit arrangements to support its strategic growth initiatives, particularly the acquisition of Pharmasset, which was a significant transaction for the company at the time. The new credit facilities provide substantial liquidity to execute this acquisition and manage ongoing operational needs.

Key Highlights

  • 1Gilead Sciences entered into new credit facilities totaling $3.00 billion to finance the acquisition of Pharmasset, Inc.
  • 2The new financing includes a $1.25 billion 5-year revolving credit facility, a $750 million short-term revolving credit facility, and a $1 billion term loan facility.
  • 3On the closing date, Gilead borrowed $750 million under the 5-year revolving credit facility and $400 million under the short-term revolving credit facility.
  • 4The full $1 billion term loan was also borrowed on the closing date, directly funding the Pharmasset acquisition and related expenses.
  • 5Gilead Sciences terminated its previous $1.25 billion Five-Year Revolving Credit Agreement dated December 18, 2007.
  • 6The credit agreements include provisions for revolving credit loans, swing line loans, and letter of credit sub-facilities.
  • 7Proceeds from these facilities are earmarked for the Pharmasset acquisition, refinancing existing debt, and general corporate purposes.

Frequently Asked Questions

The primary purpose of these new credit facilities is to fund Gilead Sciences' acquisition of Pharmasset, Inc. The proceeds will also be used to refinance existing debt, pay related fees and expenses, and for general corporate purposes and working capital requirements.

Gilead Sciences raised a total of $3.00 billion through three new credit agreements: a $1.25 billion 5-year revolving credit facility, a $750 million short-term revolving credit facility, and a $1 billion term loan facility.

Yes, Gilead Sciences drew significant amounts immediately upon closing. The company borrowed $750 million under the 5-year revolving credit facility, $400 million under the short-term revolving credit facility, and the full $1 billion term loan was also borrowed on the closing date.

Gilead Sciences fully prepaid and terminated its previous $1.25 billion Five-Year Revolving Credit Agreement dated December 18, 2007, as part of entering into these new financing arrangements.